Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript
Nadim AhmedPresident, CEO & Director All right. Good evening, everyone. Thanks for coming as we look forward to discussing the compelling initial results for CLN-049 that were presented at ASH today and also look forward to the promise of CLN-049 for patients with AML. So our disclosure slide. So as outlined in the slide, during this event, management will be making certain forward-looking…











